Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: Comparison between LAK cell and CTL therapy

Journal of Immunotherapy

Volumn 19, Issue 3, 1996, Pages 218-223

  Haruta, Ikuko ^a   Yamauchi, Katsumi ^a   Aruga, Atsushi ^a   Komatsu, Tatsuji ^b   Takasaki, Ken ^a   Hayashi, Naoaki ^a   Hanyu, Fujio ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b Yokohama National University   (Japan)

Author keywords

Adoptive immunotherapy; Cytotoxic T cells; Hepatocellular carcinoma; LAK cells

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ADULT; ADVANCED CANCER; ARTICLE; CANCER REGRESSION; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; LYMPHOKINE ACTIVATED KILLER CELL; MALE; PRIORITY JOURNAL;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, LYMPHOKINE-ACTIVATED; LIVER NEOPLASMS; MALE; MIDDLE AGED; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME;

EID: 0030039155     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199605000-00006     Document Type: Article

References (21)

1. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokineactivated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-92.
2. Komatsu T, Yamauchi K, Furukawa T, Obata H. Transcatheter arterial injection of autologous lymphokine-activated killer (LAK) cells into patients with liver cancers. J Clin Immunol 1990;10:167-74.
3. Rosenberg SA, Lotze MT, Muul LM, et al. Progress report on the treatment of 157 patients with advanced cancer lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-97.
4. West WH, Tauer KW, Yannelli JR, et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987;316:898-905.
5. Ohnishi S, Saibara T, Fujikawa M, et al. Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma. Hepatology 1989;114:283-90.
6. Ettinghausen SE, Puri PK, Rosenberg SA. Increased vascular permeability in organs mediated by systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J Natl Cancer Inst 1988;80:177-80.
7. Ishikawa T, Imawari M, Moriyama T, et al. Immunotherapy of hepatocellular carcinoma with autologous lymphokineactivated killer cells and/or recombinant interleukin 2. J Cancer Res Clin Oncol 1988;114:283-90.
8. Okuno K, Takagi H, Nakamura T, Nakamura Y, Iwasa Z, Yasutomi M. Treatment for unresectable hepatoma via selective hepatic infusion of lymphokine-activated killer cells generated from autologous spleen cells. Cancer 1986; 58: 1001-6.
9. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986;233:1318-21.
10. Yoo Y-K, Heo DS, Hata K, Van Thiel DH, Whiteside TL. Tumor-infiltrating lymphocytes from human colon carcinomas. Gastroenterology 1990;98:259-68.
11. Aruga A, Yamauchi K, Takasaki K, Furukawa T, Hanyu F. Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer: characterization and clinical utilization. Int J Cancer 1991;49:19-24.
12. Ichino Y, Ishikawa T. Generation of human cytotoxic T lymphocytes against fresh autologous and allogenic solid tumors by mixed lymphocyte-tumor-cell culture with T cell growth factor. Auris Nasus Larynx 1985;12(suppl 2):S226-33.
13. Maeda N, Hashimoto S, Miyazawa H, Takata M, Yamamoto H, Fujimoto S. Augmentation of human cytotoxic T lymphocytes against autologous tumor by a factor released from human monocytic leukemia cell lines. Jpn J Cancer Res 1989;80:537-45.
14. Vanky F, Gorsky T, Massucci MG. Lysis of tumor biopsy cells by autologous T lymphocytes activated in mixed cultures and propagated with T cell growth factor. J Exp Med 1982;155:83-95.
15. Nitta T, Sato K, Yagita H, Okumura K, Ishii S. Preliminary trial of specific targeting therapy against malignant glioma. Lancet 1990;335:368-70.
16. Takahashi H, Nakada T, Puisieux I. Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice. Science 1993;259:1460-3.
17. Isserbacher KJ, Dienstag JL. Tumors of the liver. In: Isserbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Principles of internal medicine. New York: McGraw-Hill, 1994:1495-7.
18. Okuda K. Epidemiology of primary liver cancer. In: Tobe T, ed. Primary liver cancer in Japan. Tokyo: Springer-Verlag, 1992:3-9.
19. Phgh RN, Murray-Lyon IM, Dawson JL, et al. Transsection of oesophagus for bleeding varices. Br J Surg 1973;60:646-9.
20. The international TNM staging system for liver cancer. In: Beahrs OH, et al., eds. The manual for staging of cancer. Philadelphia: JB Lippincott, 1988:88.
21. Matory YL, Chang AE, Lipford EH III, et al. Toxicity of recombinant human IL-2 in rat following intravenous infusion. J Biol Response Mod 1985;4:377-90.